利妥昔单抗治疗慢性淋巴细胞白血病

Future Prescriber Pub Date : 2009-01-19 DOI:10.1002/fps.37

Steve Chaplin MSc, MRPharmS

{"title":"利妥昔单抗治疗慢性淋巴细胞白血病","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.37","DOIUrl":null,"url":null,"abstract":"<p>Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first-line treatment option for CLL in combination with fludarabine and cyclophos-phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"9 3","pages":"11-15"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.37","citationCount":"0","resultStr":"{\"title\":\"Rituximab therapy for chronic lymphocytic leukaemia\",\"authors\":\"Steve Chaplin MSc, MRPharmS\",\"doi\":\"10.1002/fps.37\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first-line treatment option for CLL in combination with fludarabine and cyclophos-phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"9 3\",\"pages\":\"11-15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-01-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.37\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.37\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.37","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Rituximab therapy for chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first-line treatment option for CLL in combination with fludarabine and cyclophos-phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量